948 Results

People

  1. Kris
    Kris
  2. Kelsen
    Kelsen
  3. Motzer
    Motzer
  4. O'Reilly
    O'Reilly
  5. Saltz
    Saltz
  6. Tyson
    Tyson
  7. Gralla
    Gralla
  8. Hudis
    Hudis
  9. Scher
    Scher
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)
  7. Center for Hematologic Malignancies (109)
  8. Genitourinary Oncology Service (106)
  9. Nursing (101)
  10. Surgery (97)
  1. "vomiting"
Formats
  1. Journal Article (896)
  2. Review (27)
  3. Conference Paper (8)
  4. Editorial (6)
  5. Research Letter (4)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Book Section (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)

More Groups

People
  1. Mark Kris (70)
  2. David Kelsen (40)
  3. Robert Motzer (39)
  4. Eileen O'Reilly (30)
  5. Leonard Saltz (30)
  6. Leslie Tyson (28)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (44)
  4. 2022 (32)
  5. 2021 (15)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Cancer (47)
  3. Clinical Cancer Research (44)
  4. Lancet Oncology (38)
  5. Gynecologic Oncology (31)
  6. Cancer Treatment Reports (26)

More Publications

Publishers
  1. Elsevier Inc. (145)
  2. American Society of Clinical Oncology (92)
  3. Elsevier Science, Inc. (74)
  4. Springer (72)
  5. Oxford University Press (64)
  6. Wiley Blackwell (63)

More Publishers

Results (948)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: Post hoc analysis of DESTINY-PanTumor02
    Journal Article

    Oaknin, A.; Lee, J. Y.; Makker, V.; Oh, D. Y.; Banerjee, S.; González-Martín, A.; Jung, K. H.; Ługowska, I.; Manso, L.; Manzano, A.; more...
    Advances in Therapy (2024)

    Fulltext@MSK | Save
  • Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma
    Research Letter

    Shitara, K.; Shah, M. A.; Lordick, F.; Van Cutsem, E.; Ilson, D. H.; Klempner, S. J.; Kang, Y. K.; Lonardi, S.; Hung, Y. P.; Yamaguchi, K.; more...
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Progression-free survival and safety at 3.5 years of follow-up: Results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – A plain language summary
    Journal Article

    González-Martín, A.; Pothuri, B.; Vergote, I.; Graybill, W.; Lorusso, D.; McCormick, C. C.; Freyer, G.; Backes, F.; Heitz, F.; Redondo, A.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Non-emergent hemoptysis in patients with primary or metastatic lung tumors: The role of transarterial embolization
    Journal Article

    Geevarghese, R.; Petre, E.; Ziv, E.; Santos, E.; Rodriguez, L.; Zhao, K.; Sotirchos, V. S.; Solomon, S. B.; Alexander, E. S.
    European Journal of Radiology (2024)

    Fulltext@MSK | Save
  • Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: A phase 1 trial
    Journal Article

    Bullock, A. J.; Schlechter, B. L.; Fakih, M. G.; Tsimberidou, A. M.; Grossman, J. E.; Gordon, M. S.; Wilky, B. A.; Pimentel, A.; Mahadevan, D.; Balmanoukian, A. S.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • COLUMBIA-1: A randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
    Journal Article

    Segal, N. H.; Tie, J.; Kopetz, S.; Ducreux, M.; Chen, E.; Dienstmann, R.; Hollebecque, A.; Reilley, M. J.; Elez, E.; Cosaert, J.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: The phase 1b BRUIN trial
    Journal Article

    Roeker, L. E.; Woyach, J. A.; Cheah, C. Y.; Coombs, C. C.; Shah, N. N.; Wierda, W. G.; Patel, M. R.; Lamanna, N.; Tsai, D. E.; Nair, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Peripheral nerve blocks and opioid use after ACL reconstruction in adolescents
    Correspondence

    Kattail, D.; Hagen, J. G.; Alrayashi, W.
    Orthopedics (2024)

    Fulltext@MSK | Save
  • Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
    Journal Article

    Fontana, E.; Rosen, E.; Lee, E. K.; Højgaard, M.; Mettu, N. B.; Lheureux, S.; Carneiro, B. A.; Cote, G. M.; Carter, L.; Plummer, R.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save
  • Durability of response with selpercatinib in patients with RET -activated thyroid cancer: Long-term safety and efficacy from LIBRETTO-001
    Journal Article

    Wirth, L. J.; Brose, M. S.; Subbiah, V.; Worden, F.; Solomon, B.; Robinson, B.; Hadoux, J.; Tomasini, P.; Weiler, D.; Deschler-Baier, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save